Melissa Karina T. O.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mocravimod as Adjunctive and Maintenance Therapy in Acute Myeloid Leukemia Undergoing Allo-HCT
- Evaluation of Axatilimab (INCA034176) and Corticosteroids in Initial Treatment of Moderate to Severe Chronic Graft-Versus-Host Disease: A Phase 3 Randomized Study
- Phase 3 Randomized Open-Label Study of Axatilimab Versus Best Available Therapy in Chronic Graft-Versus-Host Disease Post Two Systemic Therapy Lines
Data & Insights
Has run more than one trial at 64 of 136 partner sites.
Specializations
Transplant Medicine
This investigator specializes in treating chronic graft-versus-host disease, focusing on innovative therapeutic approaches for patients who have undergone transplantation procedures.
- Post-transplant complications
- Immunological responses
- Transplant outcomes
Their research encompasses the evaluation of novel treatment combinations involving corticosteroids for managing transplant-related complications.
Immunotherapy
The investigator's work involves studying targeted immunological treatments in transplant medicine, particularly focusing on novel therapeutic agents for immune system modulation.
- Immune response modification
- Therapeutic antibodies
- Combined treatment approaches
Their expertise extends to investigating new immunotherapeutic strategies for chronic conditions following transplantation.
Clinical Research
The investigator conducts research in advanced therapeutic development, with particular emphasis on treatments for complex immunological conditions.
- Treatment optimization
- Patient outcomes
- Therapeutic efficacy
Their work includes evaluating the effectiveness of combination therapies in managing transplant-related immune responses.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.